Table 1 Patient and tumor characteristics
From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
| Characteristic | All (n = 38) | Cohort 1 (HER2-negative) (n = 9) | Cohort 2 (HER2-positive) (n = 29) |
|---|---|---|---|
| No. of patients (%) | No. of patients (%) | No. of patients (%) | |
| Age, years | |||
| Median (range) | 48 (31–62) | 46 (31–57) | 48 (32–62) |
| Sex | |||
| Female | 38 (100) | 9 (100) | 29 (100) |
| Male | 0 (0) | 0 (0) | 0 (0) |
| Race | |||
| White | 34 (89) | 8 (89) | 26 (90) |
| Black or African-American | 1 (3) | 1 (11) | 0 (0) |
| Asian | 3 (8) | 0 (0) | 3 (10) |
| Ethnicity | |||
| Hispanic or Latino | 1 (3) | 0 (0) | 1 (3) |
| Non-Hispanic | 37 (97) | 9 (100) | 28 (97) |
| ECOG PS at baseline | |||
| 0 | 24 (63) | 4 (44) | 20 (69) |
| 1 | 9 (24) | 3 (33) | 6 (21) |
| 2 | 5 (13) | 2 (22) | 3 (10) |
| Stage at initial diagnosis | |||
| I | 5 (13) | 1 (11) | 4 (14) |
| II | 13 (34) | 4 (44) | 9 (31) |
| III | 7 (18) | 1 (11) | 6 (21) |
| IV | 13 (34) | 3 (33) | 10 (34) |
| Receptor status at initial diagnosis | |||
| ER and/or PR+, HER2-negative | 7 (18) | 5 (56) | 2 (7)b |
| ER and/or PR+, HER2-positive | 14(37) | 1 (11)a | 13 (45) |
| ER and PR negative, HER2-positive | 14(37) | 0 (0) | 14 (48) |
| ER, PR, and HER2-negative | 3 (8) | 3 (33) | 0 (0) |
| Disease-free interval | |||
| < 2 years | 22 (58) | 7 (78) | 15 (52) |
| > 2 years | 16 (42) | 2 (22) | 14 (48) |
| Interval from metastatic diagnosis to CNS diagnosis (median [months], range) | 14.8 (0–107) | 5.9 (0–44.7) | 16.6 (0–107) |
| Interval from CNS diagnosis to study entry (median [months], range) | 15.7 (0.2–63.6) | 11.0 (0.4–25.5) | 19.8 (0.2–63.6) |
| Number of metastatic disease sites (median, range) | 4 (1–5) | 4 (1–5) | 4 (1–5) |
| Sites of disease | |||
| CNS | 38 (100) | 9 (100) | 29 (100) |
| Lung or pleural effusion | 19 (50) | 6 (67) | 13 (45) |
| Liver | 17 (45) | 4 (44) | 13 (45) |
| Bone | 26 (68) | 7 (78) | 19 (66) |
| Breast or chest wall | 5 (13) | 1 (11) | 4 (14) |
| Other | 15 (39) | 4 (44) | 11 (38) |
| Median (range) | Median (range) | Median (range) | |
| Baseline CNS disease volume (in cc) | 5.3 (0.7, 58.8) | 8.2 (2.1, 24.7) | 3.6 (0.7, 58.8) |
| No. of patients (%) | No. of patients (%) | No. of patients (%) | |
| Number of target CNS lesions | |||
| 1 | 9 (24) | 2 (22) | 7 (24) |
| 2 | 14 (37) | 2 (22) | 12 (41) |
| 3 | 7 (18) | 3 (33) | 4 (14) |
| 4 | 6 (16) | 1 (11) | 5 (17) |
| 5 | 2 (5) | 1 (11) | 1 (3) |
| Median (range) | Median (range) | Median (range) | |
| Size of target CNS lesions (in mm) | 15.4 (10, 60.5) | 16 (11.7, 40.9) | 14.4 (10, 60.5) |